Clinical, Laboratory and Radiologic Course and Prognosis of COVID-19 in Cancer Patients and Comparison with General Population: A Single-Center Experience

Basit Öğe Kaydı
dc.contributor.authorErdur, Erkan
dc.contributor.authorYildirim, Ozgen Ahmet
dc.contributor.authorPoyraz, Kerem
dc.contributor.authorCan, Canan
dc.contributor.authorKomek, Halil
dc.date.accessioned2024-04-24T17:24:48Z
dc.date.available2024-04-24T17:24:48Z
dc.date.issued2021
dc.departmentDicle Üniversitesien_US
dc.description.abstractIn this study, we aimed to investigate the clinical findings and follow-up data of patients with COVID-19 and had a history of cancer, and compare these data with other COVID-19 patients. We included 2349 COVID-19 inpatients between March 2020 and July 2020. 82 of these patients were found to have a cancer diagnosis (Group 1). Patients undergoing chemotherapy were assigned to group 1A, patients receiving non-chemotherapy treatment were assigned to group 1B, cancer patients without any treatment to group 1C and non-cancer patients to group 2. These groups were compared in terms of basic demographic characteristics, symptoms, comorbidities, laboratory and imaging findings, intensive care unit (ICU) admission rate and death. The median age of the patients in group 1 was statistically higher than group 2 (61 and 52, p< 0.001). The most common cancer diagnosis was breast cancer (n= 16, 19.5%). Inflammatory parameters such as CRP and D-dimer were found to be higher in patients in group 1 than group 2 (p= 0.005 and p= 0.003, respectively). The mortality rate of the patients in group 1 was 15.8%, while the mortality rate in group 2 was 5.1% and this was statistically significantly higher (p< 0.001). Being in group 1 and group 1A were determined as the predictive parameters for death (r= 0.087, p< 0.001 and r: 0.254, p= 0.021 respectively). Our data suggests that history of cancer and active chemotherapy treatment are independent prognostic factors for severe disease and mortality in COVID-19.en_US
dc.identifier.doi10.4999/uhod.214718
dc.identifier.endpage114en_US
dc.identifier.issn1306-133X
dc.identifier.issue2en_US
dc.identifier.startpage106en_US
dc.identifier.urihttps://doi.org/10.4999/uhod.214718
dc.identifier.urihttps://hdl.handle.net/11468/19841
dc.identifier.volume31en_US
dc.identifier.wosWOS:000641690900006
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.language.isoenen_US
dc.publisherAkad Doktorlar Yayinevien_US
dc.relation.ispartofUhod-Uluslararasi Hematoloji-Onkoloji Dergisi
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCovid19en_US
dc.subjectCancer Patientsen_US
dc.subjectRetrospective Case Studyen_US
dc.titleClinical, Laboratory and Radiologic Course and Prognosis of COVID-19 in Cancer Patients and Comparison with General Population: A Single-Center Experienceen_US
dc.titleClinical, Laboratory and Radiologic Course and Prognosis of COVID-19 in Cancer Patients and Comparison with General Population: A Single-Center Experience
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu